elranatamab will enhance the level or outcome of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Elranatamab causes cytokine release syndrome (CRS) that could suppress action of CYP enzymes, leading to amplified publicity of CYP substrates.avapritinib and fentanyl transdermal both raise sedation.